SB202190 (FHPI)

Name: SB202190 (FHPI)
Brand: Selleck Chemicals
SKU: S1077
Rating: 5 (99 reviews)

For research use only.

Catalog No.S1077

99 publications

CAS No. 152121-30-7

SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo. SB202190 inhibits endothelial cell apoptosis via induction of autophagy and heme oxygenase-1. SB202190 significantly suppresses Erastin‐dependent ferroptosis.

Selleck's SB202190 (FHPI) has been cited by 99 publications

Cancer Cell, 2019, 35(5):798-815

PubMed: 31031016 ( click the link to review the publication )

Cancer Discov, 2018, 8(1):74-93

PubMed: 28923912 ( click the link to review the publication )

Nat Biotechnol, 2017, 35(6):577-582

PubMed: 28459450 ( click the link to review the publication )

Nat Biotechnol, 2016, 34(11):1161-1167

PubMed: 27723727 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(7):428-36

PubMed: 23685672 ( click the link to review the publication )

Neoplasia, 2021, 23(1):129-139

PubMed: 33316537 ( click the link to review the publication )

Redox Biol, 2020, 28:101445

PubMed: 32037305 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):771

PubMed: 32943609 ( click the link to review the publication )

Cells, 2020, 13;9(5) pii: E1209

PubMed: 32414111 ( click the link to review the publication )

Cells, 2020, 28;9(4) pii: E822

PubMed: 32231153 ( click the link to review the publication )

J Neuroinflammation, 2020, 17(1):364

PubMed: 33261639 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:6584059

PubMed: 33274004 ( click the link to review the publication )

Cell Discov, 2020, 6:35

PubMed: 32550000 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(5):3203-3216

PubMed: 32053272 ( click the link to review the publication )

Eur J Immunol, 2020, 10.1002/eji.201948363

PubMed: 32022930 ( click the link to review the publication )

Sci Rep, 2020,

PubMed: 32884042 ( click the link to review the publication )

Front Pharmacol, 2020, 11:758

PubMed: 32523533 ( click the link to review the publication )

Chem Biol Interact, 2020, 317:108944

PubMed: 31935364 ( click the link to review the publication )

Int J Environ Health Res, 2020, 10.1080/09603123.2020.1739236

PubMed: 32191530 ( click the link to review the publication )

Ann Surg Oncol, 2020, 10.1245/s10434-020-08790-2

PubMed: 32632882 ( click the link to review the publication )

J Thorac Dis, 2020, 12(7):3764-3773

PubMed: 32802455 ( click the link to review the publication )

J Exp Med, 2020, 217(2)

PubMed: 31753849 ( click the link to review the publication )

J Dev Biol, 2020, 8(3):E12

PubMed: 32660129 ( click the link to review the publication )
Br J Cancer, 2020, 10.1038/s41416-020-0963-y

PubMed: 32606358 ( click the link to review the publication )

Cell Prolif, 2020, e12869

PubMed: 32597573 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2020, 10(4):779-796

PubMed: 32561494 ( click the link to review the publication )

Mol Cell, 2019, 76(6):965-980

PubMed: 31588023 ( click the link to review the publication )

Theranostics, 2019, 9(13):3879-3902

PubMed: 31281520 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):718

PubMed: 31558705 ( click the link to review the publication )

Cells, 2019, 8(7)

PubMed: 31248002 ( click the link to review the publication )

Cells, 2019, 8(9)

PubMed: 31461951 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):290-306

PubMed: 30422399 ( click the link to review the publication )

Neoplasia, 2019, 22(1):1-9

PubMed: 31751859 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.29305

PubMed: 31612516 ( click the link to review the publication )

Antiviral Res, 2019, 170:104572

PubMed: 31376425 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(2):920-933

PubMed: 30394679 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(4)

PubMed: 30781441 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(10)

PubMed: 31117181 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):19409

PubMed: 31857650 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 370(2):219-230

PubMed: 31189728 ( click the link to review the publication )

Life Sci, 2019, 231:116550

PubMed: 31185235 ( click the link to review the publication )

Int J Biochem Cell Biol, 2019, 116:105610

PubMed: 31518663 ( click the link to review the publication )

Mol Immunol, 2019, 111:162-171

PubMed: 31063937 ( click the link to review the publication )

J Biol Eng, 2019, 13:82

PubMed: 31709009 ( click the link to review the publication )

J Biol Eng, 2019, 13:36

PubMed: 31061676 ( click the link to review the publication )

Microb Pathog, 2019, 130:204-212

PubMed: 30885749 ( click the link to review the publication )
Mol Cell, 2018, 71(1):117-128

PubMed: 30008317 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 29595474 ( click the link to review the publication )

Sci Signal, 2018,

PubMed: 29511118 ( click the link to review the publication )

EBioMedicine, 2018, 36:497-507

PubMed: 30190207 ( click the link to review the publication )

Front Immunol, 2018, 9:1051

PubMed: 29896191 ( click the link to review the publication )

Cancer Immunol Immunother, 2018, 67(2):271-283

PubMed: 29090321 ( click the link to review the publication )

Sci Rep, 2018, 8(1):5074

PubMed: 29568077 ( click the link to review the publication )

Stem Cells Int, 2018, 2018:9793845

PubMed: 30693038 ( click the link to review the publication )

Am J Transl Res, 2018, 10(8):2555-2566

PubMed: 30210692 ( click the link to review the publication )

Infect Immun, 2018, 22;86(9):e00233-18

PubMed: 29986890 ( click the link to review the publication )

Eur J Pharmacol, 2018, 838:129-137

PubMed: 30196111 ( click the link to review the publication )

Toxicon, 2018, 155:1-8

PubMed: 30290166 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2018, 5(3):333-352

PubMed: 29552622 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(1):38-45

PubMed: 27820799 ( click the link to review the publication )

Biomaterials, 2017, 128:44-55

PubMed: 28288348 ( click the link to review the publication )

Aging Cell, 2017, 16(3):575-584

PubMed: 28345297 ( click the link to review the publication )

Free Radic Biol Med, 2017, 104:280-297

PubMed: 28131902 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 323:44-52

PubMed: 28341536 ( click the link to review the publication )

Int J Mol Med, 2017, 39(1):217-222

PubMed: 27878250 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:61-69

PubMed: 28315487 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2017, 5(2):113-130

PubMed: 29693040 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2017, 4(1):165-182

PubMed: 29204504 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2242

PubMed: 27297582 ( click the link to review the publication )
Int J Mol Sci, 2016,

PubMed: 27782092 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2016, 303:79-89

PubMed: 27174766 ( click the link to review the publication )

J Cancer, 2016, 7(8):900-9

PubMed: 27313779 ( click the link to review the publication )

J Diabetes Res, 2016, 2016:9073037

PubMed: 27635403 ( click the link to review the publication )

Oncol Rep, 2016, 35(5):3009-17

PubMed: 26986870 ( click the link to review the publication )

Inflamm Res, 2016, 65(3):193-202

PubMed: 26621504 ( click the link to review the publication )

Neurochem Res, 2016, 41(8):1969-81

PubMed: 27068033 ( click the link to review the publication )

Mol Med Rep, 2016, 14(2):1430-8

PubMed: 27278862 ( click the link to review the publication )

Oncotarget, 2016, 7(25):37407-37419

PubMed: 27270648 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10269-78

PubMed: 26831669 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

EBioMedicine, 2015, 2(12):1944-56

PubMed: 26844273 ( click the link to review the publication )

Inflamm Bowel Dis, 2015, 21(3):496-506

PubMed: 25647156 ( click the link to review the publication )

Cell Transplant, 2015, 24(3):573-88

PubMed: 25654487 ( click the link to review the publication )

Nat Commun, 2014, 5:3479

PubMed: 24632940 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Chem Res Toxicol, 2014, 27(9):1575-85

PubMed: 25148906 ( click the link to review the publication )

BMC Cancer, 2014, 14:325

PubMed: ( click the link to review the publication )

Life Sci, 2014, 108(2):63-70

PubMed: 24857982 ( click the link to review the publication )

Int Immunopharmacol, 2014, 24(1): 50-58

PubMed: 25479727 ( click the link to review the publication )

J Cell Biochem, 2014, 115(5):874-88

PubMed: 24375433 ( click the link to review the publication )

Cell Transplant, 2014, 23(4-5):641-56

PubMed: 24816456 ( click the link to review the publication )

Mol Biosyst, 2014, 10(3):605-12

PubMed: 24413303 ( click the link to review the publication )

Mol Cell Biochem, 2014, 397(1-2):131-8

PubMed: 25138701 ( click the link to review the publication )
Anticancer Agents Med Chem, 2014, 14(8):1154-60

PubMed: 24934165 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

J Biol Chem, 2010, 285(43):32824-33

PubMed: 20729213 ( click the link to review the publication )

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description

Targets

Ferroptosis ^[11] ()	p38α ^[1] (Cell-free assay)	p38β ^[1] (Cell-free assay)
	50 nM	100 nM

In vitro

SB 202190 significantly inhibits both basal and anti-Fas antibody-induced MAPKAPK 2 activity in a dose-dependent manner. SB202190 by itself is sufficient to induce cell death in Jurkat and HeLa cells through activation of CPP32-like caspases, which can be blocked by expression of bcl-2. SB202190-induced apoptosis is attenuated by p38β but augmented by p38α. ^[2] SB 202190 strongly inhibits UVB induced COX-2 protein expression in HaCaT cells, and markedly inhibits UVB induced cox-2 mRNA. ^[3] SB 202190 treatment inhibits the expression of albumin-induced proinflammatory (monocyte chemoattractant protein-1) and transforming growth factor (TGF)-beta1-induced profibrotic (procollagen-Ialpha1) genes over 50% in renal tubular cells (normal rat kidney-52E). ^[4] SB 202190 treatment induces phosphorylation of JNK in a dose- and time- dependent manner in A549 cells, induces phosphorylation of ATF-2 transcription factor, and increases AP-1 DNA binding. ^[6] SB 202190 treatment enhances the growth of THP-1 and MV4-11 cells. SB 202190 increases the phosphorylation of c-Raf and ERK, suggesting that Ras-Raf-MEK-mitogen-activated protein kinase (MAPK) pathway activation is involved in the leukemia cell growth induced by SB 202190. ^[7]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HCT-116	NGrrc4dHfW6ldHnvckBCe3OjeR?=	MnHzNlUh\|ryP	NVP4U5A1OzBibXnu	M1fRd2ROW00EoB?=	NVH0XFRR[XS2ZX71ZZRmeyC2aHWgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO\|aX;uJI9nKGiERD2yJIlvKHKnc4DvcpNqfmVidH:gSGE>	M{i3NVI3OjJ\|MkWx
MDA-MB-231	NHnuVnFHfW6ldHnvckBCe3OjeR?=	M4fjOFIh\|ryP	NUjSdppNOjRiaB?=		NUfN[lVxdGW\|c3Xu[ZMhS0OOMjDpcoR2[3Srb36gZpkhXE6IzsG=	MX[yOlExODh2OB?=
rBMSCs	M{DmXWZ2dmO2aX;uJGF{e2G7	MmrZNVAh\|ryP	NXXMS5BCOi53IHi=		MYrk[ZBz\XO\|ZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCHUlugZY5lKHB\|OB?=	NEnWUlUzPjB3M{K2Oi=>
MG63	NX7y[oNLTnWwY4Tpc44hSXO\|YYm=	M3TwTVExNzJyL{OwJO69VQ>?	NInlV4szPCCq		M{fWVpNq\26rZnnjZY51dHliZHXjdoVie2W\|IITo[UBt\X[nbDDv[kBxcG:\|cHjvdplt[XSnZDDwN\|ghcW6mdXPl[EBjgSCFZFPsNkBqdiCjIHPvcoNmdnS{YYTpc44hNWSncHXu[IVvfCCvYX7u[ZI>	NFn5PIozPTl7OEOxNi=>
MG63	M3XTSGFxd3C2b4Ppd{BCe3OjeR?=	Ml7pNVAwOjBxM{Cg{txO	MkjnNlQhcA>?		M3TlN5Nq\26rZnnjZY51dHliZHXjdoVie2WmIITo[UBieG:ydH;zbZMhemG2ZTDv[kBOTzZ\|IHnu[JVk\WRiYomgR4REdDJ?	NGnVTIwzPTl7OEOxNi=>
HTSMCs	M3qw[WZ2dmO2aX;uJGF{e2G7	MkfqNE4yNzFxMUCg{txO	M1q3TVEhcA>?		Mn[ybY5pcWKrdHXkJGNQWk1vMj3pcoR2[2WmIFjPMVEheHKxdHXpckBt\X[nbIOgZY5lKG2UTlGg[ZhxemW\|c3nvci=>	MmKwNlU6OjF2NkS=
MIA PaCa-2	MWfGeY5kfGmxbjDBd5NigQ>?	M4\yb\|IxyqEQvF2=	MV6yOEBp		NXTxVIt5emWmdXPl[EBt[WO2YYTlJIFk[3WvdXzheIlwdiCrbjDjc41jcW6jdHnvckB4cXSqIHLveIghOi2GRzDhcoQhTC2jbHzvd4XDqA>?	MorDNlU5QDh2OEm=
MIA PaCa-2	NYXtfXk3TnWwY4Tpc44hSXO\|YYm=	M2XHdVIxyqEQvF2=	NYXacoVvOjRiaB?=		NVu4XZVKemW\|dXz0d{BqdiCjIH3v[IV{fCCrbnjpZol1cW:wIH;mJGhKTi1zzsGgdJJwfGWrbjDhZ4N2dXWuYYTpc44>	MVmyOVg5QDR6OR?=
BxPC-3	MWrGeY5kfGmxbjDBd5NigQ>?	M3Lld\|IxyqEQvF2=	NWS2XlFyOjRiaB?=		MVvy[ZN2dHS\|IHnuJIEhdW:mZYP0JIlvcGmkaYTpc44hd2ZiSFnGMVHPuSCycn;0[YlvKGGlY4XteYxifGmxbh?=	MYOyOVg5QDR6OR?=
AsPC-1	MojSSpVv[3Srb36gRZN{[Xl?	NXG0b2hrOjEEoN88US=>	M13EbFI1KGh?		NGLKcXJz\XO3bITzJIlvKGFibX;k[ZN1KGmwaHnibZRqd25ib3[gTGlHNTIQsTDwdo91\WmwIHHjZ5VufWyjdHnvci=>	MmDUNlU5QDh2OEm=
MIA PaCa-2	NFX5WG5HfW6ldHnvckBCe3OjeR?=	NUnWZYJDOjEEoN88US=>	NIHPW2ozPCCq		MWnlcohidmOnczDjcIVifmGpZTDv[kBRSVKSIIfo[Y4h[2:vYnnu[YQhf2m2aDDncJVkd3OnIHHuZYxw\3N?	NV;yVm1KOjV6OEi0PFk>
MIA PaCa-2	NV3yUHdpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHUTm5yOjEEoN88US=>	Ml\uNkBp		NVnkdVRme2Wwc3n0bZpmeyClZXzsJIxqdmW\|IITvJJRz\WG2bXXueEB4cXSqIEKtSGch[W6mIFStZYxtd3On	NFm2S\|czPTh6OES4PS=>
BxPC-3	NXvEbIJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVyyNOKh\|ryP	MV2yJIg>		MVvz[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U>	MXOyOVg5QDR6OR?=
AsPC-1	NFvvRVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUCyNOKh\|ryP	NGW3dXkzKGh?		Mlfid4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm	MmfUNlU5QDh2OEm=
HEY	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XvN\|IxyqEQvF2=	NIO2TYYzKGh?		MVPz[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U>	M3\IPFI2QDh6NEi5
OVCAR-3	NFrGUYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV[yNOKh\|ryP	NXTmfYF1OiCq		NUe5[HlXe2Wwc3n0bZpmeyClZXzsJIxqdmW\|IITvJJRz\WG2bXXueEB4cXSqIEKtSGch[W6mIFStZYxtd3On	M4fOdlI2QDh6NEi5
SK-OV-3	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWSyNOKh\|ryP	MUGyJIg>		M1rtSpNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>?	M{TVVFI2QDh6NEi5
MH7A	NIr4VXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NG\pPHgzPCCq		M4CyZpJmcW6ob4Lj[ZMhfGinIHnubIljcXSxcomg[YZn\WO2czDv[kBZSU5?	MkHSNlU5PjJ7Nk[=
MH7A	NWLOcFdqSXCxcITvd4l{KEG\|c3H5	Mm\lNlUh\|ryP	M{\4PFI1KGh?		NXvoS5JDemW4ZYLz[ZMh[2WubDDjfYNt\SCjcoLld5QhcW6mdXPl[EBjgSC[QV6gZY5lKGOjdYPl[EBieG:ydH;zbZMhd2ZiY3XscJMhfmmjIHHjeIl3[XSrb36gc4YhUk6N	MYmyOVg3Ojl4Nh?=
SCC25	M13IOWZ2dmO2aX;uJGF{e2G7	MVuyNEDPxE1?	MkTaNlQhcA>?		MUXpcoNz\WG\|ZYOgZZV1d3CqYXf5JIxmfmWu	MnX6NlU5OzR2MEC=
HaCaT	MkfySpVv[3Srb36gRZN{[Xl?	MWe1JOK2VQ>?	NWfk[o1VOjRiaB?=		MVnpcohq[mm2czDJSm4u\|rNvaX7keYNm\CCFQ1yyNkBxem:mdXP0bY9vKGyndnXsdy=>	MUOyOVg{PDN3Mx?=
HaCaT	MlWzSpVv[3Srb36gRZN{[Xl?	MVW1JOK2VQ>?	MnzaNlQhcA>?		Mo\LbY5pcWKrdIOgTWZPNc7zLXnu[JVk\WRiQ1PMNlIheHKxZIXjeIlwdiCuZY\lcJM>	NX7pZ\|k4OjV6M{SzOVM>
HPAEpiCs	NHHXSo5HfW6ldHnvckBCe3OjeR?=	Ml71NU8{NzFyIN88US=>	MoTrNUBp		NV7lOY1wemWmdXPld{BUOVBvaX7keYNm\CCLQ1HNMVEheHKxdHXpckBidmRibWLORUBmgHC{ZYPzbY9vKGGwZDDwdo9ud3SncjDhZ5Rqfmm2eR?=	NGXofpEzPTd\|NEmwNC=>
HPAEpiCs	Mm\HSpVv[3Srb36gRZN{[Xl?	NU\oVJg3OS9\|L{GwJO69VQ>?	M4LXdVEhcA>?		NFj3NpZqdmirYnn0d{BUOVBvc4TpcZVt[XSnZDDBb5QheGixc4Doc5J6dGG2aX;uJEDDqA>?	MX2yOVc{PDlyMB?=
HPAEpiCs	MkPBSpVv[3Srb36gRZN{[Xl?	NF\S[lcyNzNxMUCg{txO	M3LqT\|EhcA>?		NELWWFlqdmirYnn0d{BUOVBidHnt[U1l\XCnbnTlcpRtgSC\|dHnteYxifGWmIHOtTpVvKHCqb4PwbI9zgWyjdHnvci=>	NIXMXGczPTd\|NEmwNC=>
K562	NH\MRmlHfW6ldHnvckBCe3OjeR?=	MWmxNOKh\|ryP	MkHBNeKhcA>?	M2DQNGROW09?	M1zkeIlvcGmkaYTzJJF2cW6jY4LpcoUucW6mdXPl[EBxOzhiTVHQT{BxcG:\|cHjvdplt[XSrb36=	Mn7ONlU3QDRyNEO=
PANC-1	NFLDUIlHfW6ldHnvckBCe3OjeR?=	NF;TdnkyOCEQvF2=	NH;6XlcyKGh?		MmPy[Y5p[W6lZYOgeIhmKGG3dH;wbIFocWNiZX\m[YN1yqB?	NH6zO4gzPTZ\|MkKyNi=>
BxPC-3	MYfGeY5kfGmxbjDBd5NigQ>?	MnH0NVAh\|ryP	M4nSNFEhcA>?		MYHlcohidmOnczD0bIUh[XW2b4DoZYdq[yCnZn\lZ5TDqA>?	MVeyOVY{OjJ{Mh?=
K562	NYjQXG83TnWwY4Tpc44hSXO\|YYm=	M2\IdlAvOjVvMTFOwG0>	M4XacVI1KGh?		MYPzeZBxemW\|c3XzJJJme3[ncnH0do9tNWmwZIXj[YQhUDKDWDDwbI9{eGixconsZZRqd25?	MUeyOVYyQTN7Mh?=
THP-1	MX\GeY5kfGmxbjDBd5NigQ>?	MVG1JOK2VQ>?	MnrWNkBp		NEPlNWx{cWewaX\pZ4FvfGy7IHH0eIVvfWG2ZYOgd4VkemW2aX;uJI9nKEmOLUJOtUBqdmS3Y3XkJIJ6KDJ5T1jDbI9tKHCudYOgSnNNNTIEoB?=	Mnz4NlU2QTh4NkG=
WB	NGHqRnVHfW6ldHnvckBCe3OjeR?=	MX2yNQKBkc7:TdMg	M3WxOVMx6oDLbXnu		M3nM[YRm[3KnYYPld{B1cGViTGDTMUBweiCOVFGtbY5lfWOnZDDJUE03KGGwZDDUUmYu\|rIEoIDyc4R2[3Srb36=	NXm5bGNoOjV3M{C2PFI>
RAW 264.7	NHTJO2xHfW6ldHnvckBCe3OjeR?=	MWixNOKh\|ryP	NWnHb2p4OzEkgJntbY4>		MnrJbY5lfWOnczDjbIFz[WO2ZYLpd5Rq[yC4YXP1c4xifGmxbjDv[kBQS3QEoB?=	MUOyOVQ3OTN7OR?=
RAW 264.7	NVz1WJNiTnWwY4Tpc44hSXO\|YYm=	MXyxNOKh\|ryP	MkCzN\|DjiImvaX6=		Mo[2ZZR1\W63YYTld{B1cGViZX\m[YN1eyCxZjDPVGchd25ib4P0[Y9kdGG\|dDDy[ZRz[WO2aX;u	MkO3NlU1PjF\|OUm=
HaCaT	NGnITpNHfW6ldHnvckBCe3OjeR?=	NXr6R29vPDEEoN88US=>	M4KyOVMuOjRiaB?=	MXTEUXNQ	NWq1XlhLemWmdXPld{B1cGViYXPjeY12dGG2aX;uJI9nKFqRLUG=	NIXLTI0zPTR\|NUS4OS=>
H9c2	M2PY[mZ2dmO2aX;uJGF{e2G7	M4fBOVUxyqEQvF5CpC=>	NEnuTXQyOiCq		NHfK[mNz\WS3Y3XzJGxFUCC{ZXzlZZNmKGGwZDDNUXAhdG:\|cx?=	NF7LNnczPTJ2NUixPC=>
HSCs	Mom0RZBweHSxc3nzJGF{e2G7	NIfB[2gzPSEQvF2=	MXSyOOKhcA>?		NIDwUmV{cWewaX\pZ4FvfGy7IHH0eIVvfWG2ZYOgWGcucW6mdXPl[EBi[3SrdnH0[YQhUFOFczDhdI9xfG:\|aYO=	M1TEPFI1QTZzOUWw
THP-1	NXXqRVZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlHXO\|IhcA>?	M37zOmROW09?	MlfhTWM2OD12LkhOwG0>	M4TCXVI1QDF3MEi3
MDDCs	NEezdVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUC3NkBp	NEHvN3pFVVOR	M3HncmlEPTB{LkhOwG0>	M4LtclI1QDF3MEi3
MDDCs	M{nZfmZ2dmO2aX;uJGF{e2G7	NFH3TlcxNTF3IN88US=>	M1[0S\|Q5KGh?	NVXOZ5E6TE2VTx?=	M{GzTJN2eHC{ZYPz[ZMhUU[QLd8xJIFv\CCLUD2xNEBxem:mdXP0bY9vyqB?	NUjCRnRwOjR6MUWwPFc>
MDDCs	M2Wxb2Z2dmO2aX;uJGF{e2G7	NIW2OXIxNTF3IN88US=>	NE\WOI01QCCq	NUDqR2I4TE2VTx?=	M1nWPIlvcGmkaYTzJG1KWC1zYTygUWlRNTGkIHHu[EBTSU6WRWOgdJJw\HWldHnvci=>	M2L5VVI1QDF3MEi3
MDDCs	MmTzSpVv[3Srb36gRZN{[Xl?	NXvLblVvOTBizszN	NIHhfWo{NjViaB?=	M3zBeGROW09?	M4HyXIJtd2OtczDFRm9XKEeSLDDieZQhdm:2IG\TWkBIKG2nZHnheIVlKGWwdIL5JIlvfG9iaIXtZY4hVUSGQ4O=	NV;HVG46OjR6MUWwPFc>
macrophages	NWn1VJVnTnWwY4Tpc44hSXO\|YYm=	NHnrVXUy6oDLzszN	MUm0MlXjiImq		M{jmXoNwdXCuZYTlcJkhcW6qaXLpeJMhVVRvSVnJMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCQRj5OvmI>	MW[yOFgxQDZ\|Mx?=
PDL	MYjGeY5kfGmxbjDBd5NigQ>?	MXKyNOKh\|ryPwrC=	NV22S5FROzBibXnu	NHvidYpFVVOR	NFrGXIp{cWewaX\pZ4FvfGy7IHnubIljcXS\|IITo[UB1\W6\|aXzlJIZwemOnLX3l[IlifGWmIFLNVE0zKGW6cILld5Nqd25?	Mle4NlQ2PjFyOEG=
AGS	Mn7NSpVv[3Srb36gRZN{[Xl?	M2XQbVUh\|ryP	NGm5dYM{OCCvaX6=		Mlf6d5VxeHKnc4Pld:KhOS2rbnT1Z4VlKGOjc4Dhd4UuQCCjbnSgZ4F{eGG\|ZT2zJIFkfGm4YYTpc44>	M17qSVI1PTR5OEe4
H520	NIPsPW1HfW6ldHnvckBCe3OjeR?=	M1vmcVExyqEEtV2=	MWSxJIg>	NI\yZnNFVVOR	MVvk[YNz\WG\|ZYOgeIhmKHCnbXX0doV5\WRvaX7keYNm\CCPU1iyJI1TVkFiYX7kJJBzd3SnaX6gcIV3\Wy\|	MWKyOFU{ODR5NR?=
H1703	NXzM[2VHTnWwY4Tpc44hSXO\|YYm=	MUmxNOKhyrWP	NHvVSmoyKGh?	NHflXVdFVVOR	M2PEOIRm[3KnYYPld{B1cGVicHXt[ZRz\XinZD3pcoR2[2WmIF3TTFIhdVKQQTDhcoQheHKxdHXpckBt\X[nbIO=	NGm2cFgzPDV\|MES3OS=>
H520	MYPGeY5kfGmxbjDBd5NigQ>?	NHjFZ2EyOMLiwsXN	NHPQflgyOiCq	NXjqWXhFTE2VTx?=	NYnofoZscW6qaXLpeJMheGWvZYTy[Zhm\C2nbHnjbZRm\CCPU1iyJJBzd3SnaX6gd5Ri[mmuaYT5	MoLmNlQ2OzB2N{W=
H1703	NFP4eotHfW6ldHnvckBCe3OjeR?=	M3fPZVExyqEEtV2=	MljqNVIhcA>?	NWTZTmdGTE2VTx?=	NXjFT4NkcW6qaXLpeJMheGWvZYTy[Zhm\C2nbHnjbZRm\CCPU1iyJJBzd3SnaX6gd5Ri[mmuaYT5	MXeyOFU{ODR5NR?=
H520	NX\sOXZqTnWwY4Tpc44hSXO\|YYm=	M4rKR\|ExyqEEtV2=	NXr3OmhxPiCq	NUDGd2d6TE2VTx?=	NHnnfoJ{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhdGW4ZXzzJI9nKHWkaYH1bZRqdi2lb37qeYdifGWmIF3TTFIhcW5icHXt[ZRz\XinZD30doVifGWmwrDj[YxtKGyrbnW=	M2nXblI1PTNyNEe1
H1703	MVfGeY5kfGmxbjDBd5NigQ>?	MnvuNVDDqML3TR?=	MWO2JIg>	NFHB[I1FVVOR	NYfldlY2e2mpbnnmbYNidnSueTDpcoNz\WG\|ZYOgeIhmKGyndnXsd{Bw\iC3YnnxeYl1cW5vY3;ubpVo[XSnZDDNV2gzKGmwIIDlcYV1emW6ZXSteJJm[XSnZNMgZ4VtdCCuaX7l	MlrnNlQ2OzB2N{W=
MC3T3-E1	M3PSbmZ2dmO2aX;uJGF{e2G7	M4rPVVAvOy9\|L{OwJO69VQ>?	NVHmepBDOSCq		M2XxV4F1fGWwdXH0[ZMhXE6ILd8xMYlv\HWlZXSgUW1RNTliZYjwdoV{e2mxbjDpckBiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nctMg	MWiyOFUxOjZ7Nh?=
MC3T3-E1	NFqyWpZHfW6ldHnvckBCe3OjeR?=	MnLNN\|Ah\|ryP	Mkf2NUBp		MUPheJRmdnWjdHXzJHRPTi4QsT3zeIlufWyjdHXkJJA{QCCPQWDLJJBpd3OyaH;yfYxifGmxbh?=	M{\5eVI1PTB{Nkm2
HUVECs	MoTvSpVv[3Srb36gRZN{[Xl?	MUexNOKhyrWP	M1XKTVEhcA>?		MWTpcohq[mm2czDUUmYu\|rFvaX7keYNm\CCFWFPMNUBxem:mdXP0bY9v	MWCyOFQ5Pzl4NB?=
AGS	NVnsbVNkTnWwY4Tpc44hSXO\|YYm=	MkLtNVDDqML3TR?=	NHrNW2c{OMLibXnu		MYnpcohq[mm2czDJUE0y\|rJvaX7keYNm\CCjY4TpeoF1cW:wIH;mJJA{QA>?	MmixNlQ1Pzl4OEG=
MKN-45	MnHISpVv[3Srb36gRZN{[Xl?	MYSxNOKhyrWP	NEH6eFU{OMLibXnu		M{XZWIlvcGmkaYTzJGlNNTIQsj3pcoR2[2WmIHHjeIl3[XSrb36gc4YheDN6	NVT2PHlVOjR2N{m2PFE>
AGS	NVzwWod5TnWwY4Tpc44hSXO\|YYm=	MnLFNVDDqML3TR?=	NXX0ZWFFOzEEoH3pci=>		NVjOcGNy[XS2ZX71ZZRmeyCLTD2x{tIucW6mdXPl[EBISSClZXzsJI1q\3KjdHnvckBidmRiaX72ZZNqd25?	M1PMS\|I1PDd7Nkix
MKN-45	MmfxSpVv[3Srb36gRZN{[Xl?	NWrjOJZLOTEEoNM1US=>	MVuzNOKhdWmw		MX3heJRmdnWjdHXzJGlNNTIQsj3pcoR2[2WmIFfBJINmdGxibXnndoF1cW:wIHHu[EBqdn[jc3nvci=>	NWi5VnlMOjR2N{m2PFE>
AGS	MXzGeY5kfGmxbjDBd5NigQ>?	MVmxNOKhyrWP	MorrN\|DDqG2rbh?=		MUTzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCLbD2x{tIucW6mdXPl[EBOVVB{IHHu[EBOVVB7IH3SUmEh\XiycnXzd4lwdg>?	M{D0WlI1PDd7Nkix
MKN-45	NV\ZZWRsTnWwY4Tpc44hSXO\|YYm=	NYrtVZdWOTEEoNM1US=>	M4jUWVMxyqCvaX6=		MWPzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCLbD2x{tIucW6mdXPl[EBOVVB{IHHu[EBOVVB7IH3SUmEh\XiycnXzd4lwdg>?	NYfoXnA1OjR2N{m2PFE>
DCs	NF3FW5VHfW6ldHnvckBCe3OjeR?=	Mn\QNlDDqM7:TR?=	Ml;UNeKhcA>?		MlPH[IVkemWjc3XzJGlNNTF{IIDyc4R2[3Srb36=	NXmycI84OjR2M{S2N\|Y>
HUVEC	MVfGeY5kfGmxbjDBd5NigQ>?	M3nyV\|IxKM7:bdMg	MV21JIg>	MXrEUXNQ	M{\IfpJm\HWlZYOgZ5l1d2urbnWg[ZhxemW\|c3nvckBt\X[nbIOgbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK=	NWTvNYdHOjRzOEmwOlI>
A 549	NVixdJF3TnWwY4Tpc44hSXO\|YYm=	M{Dy[\|UxKM7:TR?=	MonaNUBp		NUXmZYRO\GWlcnXhd4V{KHSqZTDs[ZZmdCCxZjDJUE05yqB?	Ml6wNlQyPzl4OEi=
H520	NYf0fms5TnWwY4Tpc44hSXO\|YYm=	M3XYdlUwOTBizszN	MmjyNUBp	M1PiOWROW09?	NYnPbnR4\GWlcnXhd4V{KE2VSEKgdJJwfGWrbjDhd{B4\WyuIHHzJI1TVkFibHX2[Yx{KGmwIHfl[ol1cW6rYj3lfJBwe2WmIHPlcIw>	NFHudGszPDF\|OEmwNy=>
H1703	NF[2eplHfW6ldHnvckBCe3OjeR?=	MWq1M\|ExKM7:TR?=	M4L5SlEhcA>?	NX\rXXRYTE2VTx?=	NF[4N\|dl\WO{ZXHz[ZMhVVOKMjDwdo91\WmwIHHzJJdmdGxiYYOgcXJPSSCuZY\lcJMhcW5iZ3XmbZRqdmmkLXX4dI9{\WRiY3XscC=>	MUOyOFE{QDlyMx?=
H520	MonqSpVv[3Srb36gRZN{[Xl?	M2XuclExyqEEtV2=	MVGxNkBp	M4TvPWROW09?	NUDGS5ZK\GWlcnXhd4V{KE2VSEKgcXJPSSCjbnSgdJJwfGWrbjDzeIFjcWyrdImgbY4h\2WoaYTpcoljNXS{ZXH0[YQhVlOFTFOgZ4VtdHN?	MnTDNlQyOzh7MEO=
H1703	NIHNNFNHfW6ldHnvckBCe3OjeR?=	MVKxNOKhyrWP	NWXlNFZWOTJiaB?=	NHzROlhFVVOR	NUjkU5lw\GWlcnXhd4V{KE2VSEKgcXJPSSCjbnSgdJJwfGWrbjDzeIFjcWyrdImgbY4h\2WoaYTpcoljNXS{ZXH0[YQhVlOFTFOgZ4VtdHN?	NIHMdpAzPDF\|OEmwNy=>
MCF-7	NXPWNGtIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUSxNOKh\|ryP	MVmyOOKhcA>?		NF\ydZJqdmirYnn0d{B1cGViQ2KxNFgucW6mdXPl[EBk\WyuIHTlZZRp	M2HOcVI1OTJ6OEWz
HPAEpiCs	NX21OXVGTnWwY4Tpc44hSXO\|YYm=	MnHCNE4yNzFxMUCg{txO	NGDh[5IyKGh?		NI\zS5dqdmirYnn0d{BVVkZvzsGtbY5lfWOnZDDjVGxCOsLicILveIVqdiCjbnSgcXJPSSCneIDy[ZN{cW:w	NF3sfZUzPDB4OUG1PC=>
podocytes	NVfa[VBITnWwY4Tpc44hSXO\|YYm=	M3jGc\|ExyqEQvF2=	NU\VSpozOSCq		M37IOIlvcGmkaYTzJHRITs7{MT3pcoR2[2WmIHHjeIl3[XSrb36gc4YheDN6TVHQT{BidmRiRYLrNU8zyqB?	NVK5U2FyOjRyM{[yNVI>
MCF-7	NHzLdWdHfW6ldHnvckBCe3OjeR?=	M3PjNFExyqEQvF2=	M2HpVlEhcA>?	NFzoSWFFVVOR	MnK2doVlfWOnczD0bIUhX0FvaX7keYNm\CCyaH;zdIhwenmuYYTl[EBxOzhiTVHQTy=>	M1voUlI1ODF7MEmw
MCF-7	M2TpPWZ2dmO2aX;uJGF{e2G7	NWn2[5E1OTEEoN88US=>	NHy2S3kzPCCq	MonvSG1UVw>?	M{ixbIlv[3KnYYPld{B1cGViV1GtbY5lfWOnZDDhdI9xfG:\|aYO=	MoLyNlQxOTlyOUC=
HAPI	NF6yXlFHfW6ldHnvckBCe3OjeR?=	M2Pxc\|ExNzJyL{SwxsDPxE1?	NEPQTGMyKGh?		NVX0So9rcW6qaXLpeJMhXEOGRD3pcoR2[2WmIICzPE9LVktiTVHQT{BxcG:\|cHjvdplt[XSrb36=	Mmj4NlM6PjlzMkC=
HAPI	NIG0N2dHfW6ldHnvckBCe3OjeR?=	M4TIb\|IxyqEQvF5CpC=>	MXKxJIg>	NUHTUY5VTE2VTx?=	M1[1PIF1fGWwdXH0[ZMhXEOGRD3pcoR2[2WmIHHjeIl3[XSrb36gc4YhcU6RUzDhcoQheHKxZIXjeIlwdg>?	M1H6R\|I{QTZ7MUKw
HepG2	NUn1TZJVTnWwY4Tpc44hSXO\|YYm=	NFrR[o8{PTBibl2=	MlvwNlQhcA>?		MYDpcohq[mm2czD0bIUh\GWpdXXsbY4ucW6mdXPl[EBi[3SrdnH0bY9vKG:oIICzPG1CWEt?	M1LqNVI{QTN\|MUm4
AGS	M2jNPWZ2dmO2aX;uJGF{e2G7	MnvINVDDqM7:TR?=	NETVSWo{OCCvaX6=		NHrYTYZqdmirYnn0d{Bk[XOyYYPlMVMh[WO2aY\heIlwdiCjbnSgbY5pcWKrdHnvckBw\iCHUlu=	NHjMZ3UzOzh3MEm5OC=>
HepG2	MmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETFcWwxNTVyIN88US=>	Mk\OOFghcA>?		MU\pcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	MnTzNlM5ODd3MEi=
BEL7404	M3i4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLEOplvOC13MDFOwG0>	M{HwblQ5KGh?		MWHpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	M2rEblI{QDB5NUC4
HL7702	MnfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnNNYwxNTVyIN88US=>	Ml\1OFghcA>?		MkO4bY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	NVPPd\|JFOjN6MEe1NFg>
HepG2	NF3ofnVHfW6ldHnvckBCe3OjeR?=	MYWwMVUxKM7:TR?=	NITiNVQzPCCq		MWXpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKHB\|ODDkc5dve3S{ZXHtJJBzd3SnaX7zJG1CWEuDUFuyMEBCXEZ{LDDNV2syKGGwZDDIV3AzPyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M3O2NlI{QDB5NUC4
BEAS-2B	Mkf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\lUXk3OTBizszN	NWHlW5FJOzBibXnu		NHzscYFz\X[ncoPld{B1cGViZHXjdoVie2Vib3[gZ4VtdCC4aXHibYxqfHliaX7keYNm\CCkeTDIR2k>	MmLyNlM4QDRyM{S=
BEAS-2B	MYfDfZRwfG:6aYT5JGF{e2G7	M2\4UFExKM7:TR?=	NX\JWHNOOzBibXnu		MUXpcohq[mm2ZXSgeIhmKGmwY4LlZZNmKGmwIFzETEBidmRiSVytPEBmgHC{ZYPzbY9v	NIXPW4gzOzd6NECzOC=>
BEAS-2B	MXHGeY5kfGmxbjDBd5NigQ>?	MkDuNVAh\|ryP	NWn1RpFTOzBibXnu		NIHv[Vdl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDjZZNx[XOnLUOsJGJi\CCjbnSg[oF{	NIjSUXczOzd6NECzOC=>
H9c2	NH;GW4NHfW6ldHnvckBCe3OjeR?=	M2O0S\|AvODFxMD6xM\|Eh\|ryP	MUGxJIg>		M4X1PIF1fGWwdXH0[ZMhXE6ILd8xMYlv\HWlZXSgUW1RNTliZYjwdoV{e2mxbjygcXJPSSCuZY\lcJMtKGGwZDDwdo9ud3SncjDhZ5Rqfmm2eR?=	NVjrdIpDOjN5N{SyOVI>
H9c2	MVrGeY5kfGmxbjDBd5NigQ>?	MkS5NUDPxE1?	NXvw[VRZOSCq		MoHUdoVlfWOnczDUUmYu\|rFiZHny[YN1dHlic4TpcZVt[XSnZDDwN\|ghVUGSSzDwbI9{eGixconsZZRqd25?	Ml3UNlM4PzR{NUK=
U937	M13GWWZ2dmO2aX;uJGF{e2G7	NXe5RWVrOTEEoN88UeKh	MnyzNUBp		MUnhZpJw\2G2ZYOgeIhmKGOjZn\lbY5mKGWoZnXjeEBwdiCPS2CtNUBidmRiUGCyRYPPuSCvUl7BJJRz[W6\|Y4LpdJRqd26jbDDs[ZZmdHN?	Mm\xNlM4ODd\|OEe=
U937	MWXGeY5kfGmxbjDBd5NigQ>?	NGLEbHEyOMLizszNxsA>	M2\yOFEhcA>?		MnLKZYJzd2ejdHXzJINi\m[naX7lMYlv\HWlZXSgUWtRNTFiZH;3ck1z\We3bHH0bY9vKGGwZDDQVFJC[87zIIXwMZJm\3WuYYTpc44>	NVW1cG1POjN5MEezPFc>
U937	MnTwSpVv[3Srb36gRZN{[Xl?	NYPoSoVCOTEEoN88UeKh	MmTENUBp		NWnSN2xWe3WycILld5NmeyClLVr1ckBidmRiQ2LFRkBxcG:\|cHjvdplt[XSrb36gbY4h[2GoZnXpcoUufHKnYYTl[EBk\Wyuc9Mg	NGXNR\|AzOzdyN{O4Oy=>
A549	NX7UOo9KTnWwY4Tpc44hSXO\|YYm=	NXvlPFRuOC5\|L{OvN\|Ah\|ryP	NH7FTZEyKGh?		NITRbnN{cWewaX\pZ4FvfGy7IHH0eIVvfWG2ZYOgRXRR\|rOVLX3l[IlifGWmIFPPXE0zKHC{b4TlbY4h[W6mIH3SUmEh\XiycnXzd4lwdiCjbnSgdJJwdW:2ZYKgZYN1cX[rdIpCpC=>	NHHHVVczOzZ6ME[3OC=>
A549	M2WxPWZ2dmO2aX;uJGF{e2G7	MlXFNVDDqM7:TdMg	NVm4bYdwOC1\|MDDtbY4>		MnTDbY5pcWKrdIOgRXRR\|rOVIHnu[JVk\WRicESyM5A1PCCPQWDLJIFv\CCyM{igUWFRUyCyaH;zdIhwenmuYYTpc44>	NYHPSG52OjN4OEC2O\|Q>
A549	NYfNO5pwTnWwY4Tpc44hSXO\|YYm=	NF3LT\|cyOMLizszNxsA>	NEXu[GEyKGh?		NVvmPFdrcW6qaXLpeJMhSVSSzsPTJIlv\HWlZXSgUmYu\|rqEIIC2OUB{fWK3bnn0JJBpd3OyaH;yfYxifGmxbjDhcoQhVkZvzsrCJJBzd22xdHXyJIFkfGm4aYT5	NYTzbWxZOjN4OEC2O\|Q>
A549	NInyXY9HfW6ldHnvckBCe3OjeR?=	MXexNOKh\|ryPwrC=	MljkNUBp		MljBdoVlfWOnczDBWHDPu1Nvc4TpcZVt[XSnZDDjVGxCOiCyaH;zdIhwenmuYYTpc47DqA>?	MkXrNlM3QDB4N{S=
A549	NWTtR5NCTnWwY4Tpc44hSXO\|YYm=	MUmxNOKh\|ryPwrC=	M{SxfFEhcA>?		NH\tNGxz\WS3Y3XzJGFVWM7\|Uz3lcohidmOnZDDlcpp6dWG2aXOgZYN1cX[rdImgc4Yh[1COQUNCpC=>	M4fH[VI{PjhyNke0
PC12	M4PRUWZ2dmO2aX;uJGF{e2G7	NGPGR4EyOC9{MD:0NEDPxE1?	NHHFXHcyyqCq		NY\MV5BkcW6qaXLpeJMhUk6NIHHu[EBxOzh?	NXLUOFJtOjN3OESzOVc>
HK-2	MUXBdI9xfG:\|aYOgRZN{[Xl?	M1npTVIxyqEQvF2=	M{fkSVI1KGh?		MYjpcohq[mm2czDFVmsh[W6mIICzPG1CWEt?	NWi2Z2x{OjN3NEOxOVE>
H9c2	NIXDdnNHfW6ldHnvckBCe3OjeR?=	M{nZZ\|HDqM7:TR?=	M13F[\|EhcA>?		MoXHdoVlfWOnczDUUmYu\|rFvaX7keYNm\CCPTWCtPUBuWk6DIHzleoVteyCjbnSgdJJwdW:2ZYKgZYN1cX[rdIm=	NYTDN4kyOjN\|NUO2PVk>
H9c2	MknBSpVv[3Srb36gRZN{[Xl?	M{LrdlHDqM7:TR?=	NHr0NmgyKGh?		Mn3TdoVlfWOnczDUUmYu\|rFvZX7oZY5k\WRiQWCtNUBxem:vb4TldkBi[3Srdnn0fS=>	NWDqeWFyOjN\|NUO2PVk>
H1650	MmH5SpVv[3Srb36gRZN{[Xl?	MkHSNVDDqM7:TdMg	M{fOT\|EhcA>?	NVr0N4tmTE2VTx?=	Mo\i[IVkemWjc3XzJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcJMhd2ZiRWLDR\|EhcW5icHHjcIl1[XinbD3lfJBwe2WmwrDj[Yxtew>?	M{S5R\|I{OjJ6Nkm2
H1703	M3rGPGZ2dmO2aX;uJGF{e2G7	MmDiNVDDqM7:TdMg	Mo\yNUBp	M3rDXWROW09?	NInRR29l\WO{ZXHz[ZMh[m:2aDDwdo91\WmwIHHu[EBuWk6DIHzleoVteyCxZjDFVmNEOSCrbjDwZYNtcXSjeHXsMYV5eG:\|ZXVCpINmdGy\|	M{HRdFI{OjJ6Nkm2
H1650	NF3IdG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX[xNOKh\|ryPwrC=	MXOxJIg>	NGe3TZpFVVOR	MmDY[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>?	M3[2elI{OjJ6Nkm2
H1703	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfjNVDDqM7:TdMg	M{DJW\|EhcA>?	M3:yVmROW09?	MljH[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>?	NF\sSmUzOzJ{OE[5Oi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	mTOR / p-S6K / S6K / p-S6 / p-AKT / p-MK2; PubMed: 26844273 EBioMedicine CRC cells were treated with 10 μM SB202190 for 2 h and analyzed for mTOR signaling and on-target inhibition of p38 by immunoblot. pJNK1 / pJNK2 / JNK1 / JNK2 ; PubMed: 18222647 Cell Signal A549 cells were treated with DMSO control or with 10 µM of SB202190 for 0.5, 1, 2, 3, 4, or 6 hours, and pJNK and unphosphorylated JNK were detected as described.	26844273 18222647
Immunofluorescence	p-p38 / MMP9; PubMed: 24479681 Mol Cancer Immunocytochemical staining and confocal microscopy confirmed that IL-1β increased activation of p38 (red), and MMP2 and MMP9 (green) expression in MKN-45 GA cells; these effects were blocked by p38 siRNA or the p38 inhibitor SB202190.	24479681
Growth inhibition assay	Cell viability ; PubMed: 26844273 EBioMedicine Top panel: CRC cells were treated with various concentrations of SB202190 for 48 h. Lower panel: CRC cells were treated with SB202190 at 10 μM for different times. Cell growth was measured by SRB assay (means ± s.d. in triplet, n = 3 in triplet).	26844273

In vivo

Inhibiting p38 by administration of SB 202190 inhibits PV IgG-induced blister formation in the passive transfer mouse model. ^[5] In the endotoxin model of sepsis, SB 202190 treatment produces a statistically significant survival benefit compared with control. ^[8]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro kinase assays: The p38α and p38β are assayed in 25 mM Tris-HCl, pH 7.5, containing 0.1 mM EGTA, with myelin basic protein (0.33 mg/mL) as substrate. Assays are performed either manually for 10 minutes at 30 °C in 50 μL incubations using [γ-³³P]ATP, or with a Biomek 2000 Laboratory Automation Workstation in a 96-well format for 40 minutes at ambient temperature in 25 μL incubations using [γ-³³P]ATP. The concentrations of ATP and magnesium acetate are 0.1 mM and 10 mM respectively. All assays are initiated with MgATP. Manual assays are terminated by spotting aliquots of incubation on to phosphocellulose paper, followed by immersion in 50 mM phosphoric acid. Robotic assays are terminated by the addition of 5 μL of 0.5 M phosphoric acid before spotting aliquots on to P30 filter mats. All papers are then washed four times in 50 mM phosphoric acid to remove ATP, once in acetone (manual incubations) or methanol (robotic incubations), and then dried and counted for radioactivity.
Cell Research: ^[2]	- Collapse Cell lines: Jurkat, and HeLa Concentrations: Dissolved in DMSO, final concentrations ~50 μM Incubation Time: 24 hours Method: Cells are serum-starved and then treated with different concentration of SB 202190 for 24 hours. Cell viability is assayed by either trypan blue exclusion or propidium iodide exclusion followed by flow cytometry analysis. The apoptotic nuclei are visualized by H33258 staining. (Only for Reference)
Animal Research: ^[5]	- Collapse Animal Models: C57BL/6J mice injected i.d. with a sterile solution of either control IgG or PV IgG Dosages: 12.5 μg Administration: Administered via i.d. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	66 mg/mL (199.19 mM)
	Ethanol	12 mg/mL (36.21 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+40%PEG300+5%Tween80+50%H2O For best results, use promptly after mixing.	8 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download SB202190 (FHPI) SDF

Molecular Weight	331.34
Formula	C₂₀H₁₄N₃OF
CAS No.	152121-30-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1=CC(=CC=C1C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Selective p38 MAPK Inhibitor

BIRB 796 (Doramapimod) : p38α-selective, Kd=0.1 nM.
Most Potent p38 MAPK Inhibitor

Skepinone-L ^New : p38α-MAPK, IC50=5 nM.
p38 MAPK Inhibitor in Clinical Trial

VX-702 : Phase II for Rheumatoid Arthritis.
Newest p38 MAPK Inhibitor

Skepinone-L ^New : Selective p38α-MAPK inhibitor with IC50 of 5 nM.

Related p38 MAPK Products

Pexmetinib (ARRY-614) ^New

Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.
SB239063 ^New

SB239063 is a potent and selective p38 MAPKα/β inhibitor with IC50 of 44 nM, showing no activity against the γ- and δ-kinase isoforms.
Ravoxertinib (GDC-0994) ^New

Ravoxertinib (GDC-0994) is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
SB203580

SB203580 (RWJ 64809, PB 203580) is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM in THP-1 cells, 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC50 of 3-5 μM. SB203580 induces mitophagy and autophagy.

Features:First reported p38 inhibitor.
Doramapimod (BIRB 796)

Doramapimod (BIRB 796) is a pan-p38 MAPK inhibitor with IC50 of 38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays, and binds p38α with K_d of 0.1 nM in THP-1 cells, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2.

Features:The first p38 MAPK inhibitor to be tested in a phase III clinical trial.
Ralimetinib dimesylate

Ralimetinib (LY2228820) dimesylate is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM in a cell-free assay, does not alter p38 MAPK activation. Phase 1/2.
Losmapimod (GW856553X)

Losmapimod (GW856553X, GW856553, GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pK_i of 8.1 and 7.6 for p38α and p38β, respectively. P38 MAPKs are involved in cell differentiation, apoptosis and autophagy. Phase 3.
PH-797804

PH-797804 is a novel pyridinone inhibitor of p38α with IC50 of 26 nM in a cell-free assay; 4-fold more selective versus p38β and does not inhibit JNK2. Phase 2.
VX-702

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

Features:Highly selective, orally active inhibitor of p38 MAPK.
TAK-715

TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

SB202190 (FHPI)